Opinion|Videos|February 10, 2025
Navigating New Treatment Options for Pediatric Atopic Dermatitis Management
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Where do you see the newer agents fitting into moderate to severe atopic dermatitis treatment?
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
ACIP votes to update hepatitis B vaccine recommendation for infants
2
New analysis highlights nirsevimab as most impactful RSV prevention strategy for infants
3
Repeal of nonmedical exemptions linked to rise in kindergarten vaccination rates
4
Christine Eng, MD, on addressing barriers to exome and genome sequencing in clinical practice
5
